Switching to Novo's Wegovy pill from obesity shots kept weight loss in study

• 194 patients who switched to the Wegovy pill lost an average of 8.8 pounds (4% of body weight) over three months, with 40% achieving 5% or more weight loss
• Around 75% of patients reported satisfaction with switching to the pill, citing convenience for travelers who don't want to refrigerate injections
• Novo also announced its next-generation drug CagriSema reduced 'food noise' and showed benefits in organ and bone health, with launch expected in early 2025

Market Summary: Novo Nordisk's Wegovy Pill Shows Promising Weight Loss Results

Key Findings

Novo Nordisk presented real-world data showing patients who switched from obesity injections to its new Wegovy pill continued losing weight. The analysis, using data from telehealth platform Ro, tracked 194 patients with obesity or overweight conditions (56% female) over three months.

Critical Data Points

• Patients switching from either Wegovy injections or Eli Lilly's Zepbound to the Wegovy pill lost approximately 4% additional weight (average 8.8 pounds) after three months
• Average starting weight before pill treatment: 221 pounds
• 40% of participants achieved 5% or more weight loss after switching
• 82% reported at least one improvement during treatment
• 75% expressed satisfaction with the pill switch
• 70% reported better-fitting clothes; 51% pursued healthier eating habits

Companies and Products

Novo Nordisk: Wegovy (injection and pill formulations), experimental drug CagriSema

Eli Lilly: Zepbound injection

Market Implications

The data suggests patients may transition from weekly injections to more convenient oral treatments without sacrificing efficacy. This could expand market access and improve patient compliance. Novo's Chief Scientific Officer Martin Holst Lange noted a clear preference shift toward oral medications, particularly among travelers concerned about refrigeration requirements.

Pipeline Development

Novo also announced CagriSema results showing reduced "food noise," improved organ health, and maintained bone density. The combination drug (semaglutide + cagrilintide) is expected to launch early next year, with additional versions coming in 2028.

Study Limitations: Real-world data cannot determine causality; results include self-reported data and may not generalize to broader populations.